5 Key Takeaways

• 1

  Glaucoma is the leading cause of irreversible blindness, with intraocular pressure (IOP) being the only modifiable risk factor for disease progression.

• 2

  New pharmacologic options, including omidenepag isopropyl and sepetaprost, have emerged, providing alternatives for patients unresponsive to traditional therapies.

• 3

  NCX 470, a nitric oxide donating eyedrop, shows promise in lowering IOP through a dual mechanism, outperforming existing treatments in clinical trials.

• 4

  The iDose TR implant offers a long-term solution for IOP control, demonstrating noninferiority to timolol with improved patient compliance over three years.

• 5

  Technicians should stay informed about new glaucoma treatments to assist patients effectively and navigate prescribing challenges like insurance coverage.